Table 2 Clinicopathological characteristics of patients in each ISH group.

From: Impact of the 2018 ASCO/CAP guidelines on HER2 fluorescence in situ hybridization interpretation in invasive breast cancers with immunohistochemically equivocal results

Characteristics

Value

ISH group 1

ISH group 2

ISH group 3

ISH group 4

ISH group 5

Age

>60

38

5

0

11

363

≤60

220

24

4

42

982

NAa

60

0

0

0

61

Tumor types

IDC

252

28

4

50

1262

ILC

1

0

0

1

29

Special types

5

1

0

2

54

NAa

60

0

0

0

61

Tumor size

>2 cm

127

15

1

20

460

≤2 cm

94

10

1

15

735

NAb

97

4

2

18

211

LN status

Positive

106

11

1

16

411

Negative

115

14

1

19

784

NAb

97

4

2

18

211

WHO grade

I

4

0

0

0

191

II

87

12

0

13

572

III

124

13

2

20

354

NAb

103

4

2

20

289

Hormone status

ER+

149

20

3

44

1152

ER−

109

9

1

9

193

PR+

130

16

3

38

1052

PR−

128

13

1

15

293

NAa

60

0

0

0

61

  1. ISH: in situ hybridization; IDC: invasive ductal carcinoma; ILC: invasive lobular carcinoma;. LN: lymph node; WHO: world health organization; ER: estrogen receptor; PR: progesterone receptor.
  2. NAa: not available for cases with missing data on the tumor characteristics. NAb: not available for cases with missing data on the tumor characteristics and not applied for samples from core needle biopsies or metastatic sites.
Back to article page